Trial Profile
Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor PF-00868554 following multiple dose administration in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2009
Price :
$35
*
At a glance
- Drugs Filibuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 07 Jan 2009 New trial record.